Dalantercept: Additional Phase II data

Data from 28 evaluable patients with metastatic RCC in the first part of the 2-part, U.S. Phase II DART trial showed that subcutaneous 0.6, 0.9 or 1.2 mg/kg dalantercept given once every 3 weeks plus ...